Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports


PersistenceMarketResearch states that the global osteoporosis drugs market will witness a CAGR of over 4.5% between 2020 and 2030.

Market Snapshot

The very first choice for osteoporosis are bisphosphonates. They are inclusive of Alendronate (Fosamax) – to be administered weekly; Risedronate (Actonel) – to be administered monthly or weekly; Ibandronate (Boniva) – quarterly intravenous (IV) infusion or monthly; and Zoledronic acid (Reclast), a yearly IV infusion; and denosumab (Xgeva, Prolia). The present-day research states that on not adhering to the prescribed intake of this drug, there could be a higher risk to spinal fractures. This factor is bound to go well with the osteoporosis drugs market in the years to come.

Plus, these days, intravenous bisphosphonates are preferred to the ones in pill form as they do not upset the stomach. 

Going Deeper

Apart from bisphosphonates, the other products used as osteoporosis drugs include calcitonin, parathyroid hormone therapy, SERM (Selective Estrogen Inhibitors Modulator), and rank ligand inhibitors. The drugs that help in bone-building include Romosozumab (Evenity), Abaloparatide (Tymlos), and Teriparadite (Forteo). They work wonders for the ones who are subject to osteoporosis due to steroids, or those who had fractures, or those who have lower bone density.


North America holds the largest market share. This could be reasoned with hoards of collaborations being worked upon by companies for enhancing the research capabilities. Europe is second-seeded. The Asia-Pacific is expected to grow at the fastest rate between 2020 and 2030 due to companies making relentless efforts in commercializing generic and branded therapeutics, that too, taking affordability into consideration. 

Competitive Landscape

The key market participants include Merck & Co., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novo Nordisk, Pfizer Inc., Amgen Inc., and Novartis International AG. Raloxifene from Dr. Reddy’s has been received very well for treating osteoporosis. DUAVEE from Pfizer Inc. comes across as a conjugated estrogen to treat/prevent post-menopausal osteoporosis. Also, Laboratorios Farmacéuticos Rovi, S.A. (ROVI), since Apr 2019, started marketing Teva Pharmaceuticals’ Tetridar for treating adults suffering from osteoporosis.

To Know More about Report @

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts